Company Profile

Targepeutics Inc
Profile last edited on: 6/5/2019      CAGE: 38KV1      UEI: JN8ARN7JB9M5

Business Identifier: Targeted therapies for cancers and asthma
Year Founded
2000
First Award
2000
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

475 West Governor Road
Hershey, PA 17033
   (717) 533-7772
   N/A
   www.targepeutics.com
Location: Single
Congr. District: 10
County: Dauphin

Public Profile

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. The firm's lead compound, GB-13, is reported as advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage. Management of the firm also report that they have licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Darren Wolfe -- CEO

  Stephen Abramson

  Sil Lutkewitte

Company News

There are no news available.